Intensifying peri-operative chemotherapy with radiotherapy in resectable gastro-esophageal junction (GEJ) and stomach cancer patients: Initial results of a prospective trial at a tertiary cancer care centre

被引：0
|
作者：
Pant, S. [1 ]
Kumar, Y. [1 ]
Misra, S. [1 ]
Singh, S. [1 ]
Singh, R. [1 ]
Kumar, S. [1 ]
机构：
[1] Sanjay Gandhi Post Grad Inst Med Sci, Lucknow, Uttar Pradesh, India
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-230
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 15 条
  • [1] Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India
    Rao T., Subramanyeshwar
    Raju, Kalidindi Venkata Vijaya Narsimha
    Patnaik, Sujit Chyau
    Reddy, Pratap
    Saksena, Ajesh Raj
    Rajappa, Senthil
    Mallavarapu, Krishna Mohan
    Santa, Ayyagari
    Gudipudi, Deleep
    Boleneni, Naren
    Usofi, Zeeba
    Gujjuru, Swathi
    Smith, Lynette
    Are, Chandrakanth
    Nusrath, Syed
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (07) : 1547 - 1557
  • [2] PHASE 2 STUDY OF TELATINIB IN COMBINATION WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED CANCER OF THE STOMACH OR GASTRO-ESOPHAGEAL JUNCTION (GEJ)
    Alsina, M.
    Ajani, J. A.
    Ko, A. H.
    Garcia De Paredes, M. L.
    Rivera, F.
    Schwartzberg, L.
    Phan, A. T.
    Whiteside, M.
    Kunkel, L. A.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 229 - 229
  • [3] Surgical complications related to peri-operative adjuvant chemotherapy in breast cancer. Results of a prospective, controlled, randomized clinical trial
    Canavese, G
    Catturich, A
    Vecchio, C
    Gipponi, M
    Tomei, D
    Sertoli, MR
    Repetto, L
    Badellino, F
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1997, 23 (01): : 10 - 12
  • [4] Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
    Ryan, D. P.
    Murphy, J.
    Mahalingam, D.
    Strickler, J.
    Stein, S.
    Sirard, C.
    Landau, S.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 108 - 108
  • [5] Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).
    Ryan, David P.
    Murphy, Janet E.
    Mahalingam, Devalingam
    Halmos, Balazs
    Sirard, Cynthia A.
    Landau, Steven B.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastro-esophageal junction: Updated results of a phase II multicenter trial
    Tomasello, Gianluca
    Liguigli, Wanda
    Toppo, Laura
    Negri, Federica
    Curti, Alessandra
    Ratti, Margherita
    Poli, Rossana
    Lazzarelli, Silvia
    Gerevini, Fabiana
    Colombi, Chiara
    Rovatti, Massimo
    Olivetti, Lucio
    Martinotti, Mario
    Passalacqua, Rodolfo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases
    Nordlinger, B.
    Sorbye, H.
    Collette, L.
    Glimelius, B.
    Poston, G. J.
    Schlag, P. M.
    Rougier, P.
    Bechstein, W.
    Walpole, E.
    Gruenberger, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] QUALITY OF LIFE RESULTS FROM A PHASE III STUDY OF TRASTUZUMAB PLUS CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION CANCER
    Ohtsu, A.
    Wang, L.
    Lim, H.
    Gourbounova, V
    Bang, Y.
    Van Cutsem, E.
    Al-Sakaff, N.
    Lehle, M.
    Hill, J.
    de Mendoza, Hurtado F.
    ANNALS OF ONCOLOGY, 2010, 21 : 14 - 14
  • [9] The relationship between pathologic nodal disease and residual tumor viability (RV) in patients with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ) receiving induction chemotherapy, surgery, and post-operative chemo-radiotherapy (CRT).
    McNamara, Michael J.
    Sohal, Davendra
    Murthy, Sudish C.
    Rybicki, Lisa A.
    Stephans, Kevin L.
    Greskovich, John
    Videtic, Gregory M. M.
    Raja, Siva
    Rodriguez, Cristina P.
    Ives, Denise I.
    Bodmann, Joanna
    Adelstein, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design
    Inci, Melisa Guelhan
    Sehouli, Jalid
    Schnura, Eva
    Lee, Marlene
    Roll, Stephanie
    Reinhold, Thomas
    Klews, Julia
    Kaufner, Lutz
    Niggemann, Phil
    Groeben, Harald
    Toelkes, Julia
    Reisshauer, Anett
    Liebl, Max
    Daehnert, Enrico
    Zimmermann, Manuela
    Knappe-Drzikova, Barbora
    Rolker, Susanne
    Nunier, Bjoern
    Algharably, Engi
    Sehouli, Adak Pirmorady
    Zwantleitner, Lena
    Krull, Andrea
    Heitz, Florian
    Ataseven, Beyhan
    Chekerov, Radoslav
    Harter, Philipp
    Schneider, Stephanie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (08) : 1304 - 1309
12